0. DOCID:28606 SCORE: 0.000872642773510714
DOCNO: 12801816
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: therapy
QUALIFIER: therapy
AUTHOR: Christine Théodore C
AFFILIATION: Institut Gustave-Roussy, 94806 Villejuif Cedex.
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Bulletin du cancer.
COUNTRY: France
TITLE: [Cured of testicular cancer]
PUBDATE: 20030401
Nowadays, testicular cancer can be cured in more than 90 % of patients. Most patients we see now as "cured" of testicular cancer were treated either with chemotherapy or with radiotherapy. We detail the complete remission criteria and the follow-up procedure. We describe the long term toxicities of treatments, the risk of second cancer and the carryover of the disease and treatments on long term quality of life, sexuality and fertility.


1. DOCID:31388 SCORE: 0.000561464274014549
DOCNO: 15557797
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Genes, BRCA1
DESCRIPTOR: Genes, BRCA2
DESCRIPTOR: Genetic Predisposition to Disease
DESCRIPTOR: Recombination, Genetic
QUALIFIER: genetics
AUTHOR: Ralph Scully R
AUTHOR: Anyong Xie A
AFFILIATION: Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215, USA.
PUBTYPE: Journal Article
JOURNALTITLE: Journal of mammary gland biology and neoplasia.
COUNTRY: United States
TITLE: BRCA1 and BRCA2 in breast cancer predisposition and recombination control.
PUBDATE: 20040701
Hereditary predisposition to breast and ovarian cancer is determined in large part by loss-of-function mutations in one of two genes, BRCA1 and BRCA2 . Early discoveries that the two genes function in the control of homologous recombination and the prevention of genomic instability have been strongly supported by subsequent work. Our aim here is to highlight new advances in the study of BRCA1 and BRCA2 , and to place these advances in the context of existing knowledge.


2. DOCID:30156 SCORE: 0.000553290524519961
DOCNO: 15806096
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: complications
QUALIFIER: toxicity
QUALIFIER: etiology
AUTHOR: Alistair J Lax AJ
AFFILIATION: Department of Microbiology, Dental Institute, King's College London, Floor 28 Guy's Tower, Guy's Hospital, London SE1 9RT, UK. alistair.lax@kcl.ac.uk
PUBTYPE: Journal Article
JOURNALTITLE: Nature reviews. Microbiology.
COUNTRY: England
TITLE: Opinion: Bacterial toxins and cancer--a case to answer?
PUBDATE: 20050401
Since the discovery that Helicobacter pylori infection leads to gastric cancer, other chronic bacterial infections have been shown to cause cancer. The bacterial and host molecular mechanisms remain unclear. However, many bacteria that cause persistent infections produce toxins that specifically disrupt cellular signalling to perturb the regulation of cell growth or to induce inflammation. Other bacterial toxins directly damage DNA. Such toxins mimic carcinogens and tumour promoters and might represent a paradigm for bacterially induced carcinogenesis.


3. DOCID:30968 SCORE: 0.000551996775779471
DOCNO: 14605452
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: therapeutic use
QUALIFIER: drug therapy
QUALIFIER: drug therapy
AUTHOR: J Lehmann J
AUTHOR: M Retz M
AUTHOR: M Hack M
AUTHOR: S Siemer S
AUTHOR: M Stöckle M
AFFILIATION: Klinik für Urologie und Kinderurologie, Universität des Saarlandes, Homburg, Deutschland.
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Onkologie.
COUNTRY: Switzerland
TITLE: [Systemic chemotherapy for transitional cell carcinoma of the urothelium]
PUBDATE: 20031001
Moderate activity of systemic chemotherapy for advanced urothelial cancer has been reported for more than 30 years. Only with the advent of potent combination therapy in the mid eighties of the past century clinically significant response rates as well as prolonged survival has been documented. This review summarizes seven Phase-III trials of systemic chemotherapy for advanced urothelial carcinoma as well as results from adjuvant and neoadjuvant Phase-III trials for muscle-invasive bladder cancer including the most recent reports.


4. DOCID:30791 SCORE: 0.000249640211425172
DOCNO: 16360471
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Laparoscopy
QUALIFIER: methods
QUALIFIER: drug therapy
QUALIFIER: drug therapy
QUALIFIER: surgery
AUTHOR: Guilherme C Lima GC
AUTHOR: Sahar Kohanim S
AUTHOR: Soroush Rais-Bahrami S
AUTHOR: Louis R Kavoussi LR
AFFILIATION: James Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, Maryland 21287, USA. guilolima@terra.com.br
PUBTYPE: Case Reports
PUBTYPE: Journal Article
JOURNALTITLE: Urology.
COUNTRY: United States
TITLE: Laparoscopic retroperitoneal lymph node dissection after prior open retroperitoneal lymphadenectomy and chemotherapy.
PUBDATE: 20051201
Laparoscopic retroperitoneal lymphadenectomy for testicular cancer is a challenging surgical procedure. Several factors can increase the difficulty, including prior chemotherapy or open surgery. We present a case of a laparoscopic "redo" postchemotherapy nodal dissection to treat a residual retroperitoneal mass in a patient with non-seminomatous germ cell tumor. This approach allowed rapid recovery, and at 2.5 years after surgery no evidence of tumor recurrence was seen.


5. DOCID:31340 SCORE: 0.000249640210957148
DOCNO: 16521433
OWNER: NLM
STATUS: In-Process
AUTHOR: Ryszard Zasławski R
AUTHOR: Paweł Surowiak P
AUTHOR: Maciej Zabel M
AFFILIATION: Szpital Wojewódzki w Legnicy, Oddzial Ginekologiczno-Połozniczy.
PUBTYPE: Journal Article
JOURNALTITLE: Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego.
COUNTRY: Poland
TITLE: [Classical and novel molecular prognostic factors in ovarian cancers]
PUBDATE: 20051201
Development of molecular biology techniques allows at present for a more rapid and more reliable diagnosis of ovarian cancers. Present paper describes genetic alterations which predispose to development of ovarian cancer and mutations which play principal role in pathogenesis of sporadic cases of the disease. Prognostic significance has also been outlined of expression of cyclooxygenase 2, ligands of P-selectin and inhibitors of complement in cells of ovarian cancer as well as their potential therapeutic significance. A separate chapter has been devoted to the potential and achievements gained using DNA microarray techniques.


6. DOCID:29373 SCORE: 0.000249635836310322
DOCNO: 14520447
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: epidemiology
QUALIFIER: epidemiology
QUALIFIER: epidemiology
AUTHOR: A Stang A
AUTHOR: C Stegmaier C
AUTHOR: K-H Jöckel KH
AFFILIATION: Epidemiology Unit, Institute for Medical Informatics, Biometry and Epidemiology, University Hospital of Essen, Hufelandstr. 55, 45122 Essen, Germany. andreas.stang@uni-essen.de
PUBTYPE: Journal Article
JOURNALTITLE: British journal of cancer.
COUNTRY: England
TITLE: Nonmelanoma skin cancer in the Federal State of Saarland, Germany, 1995-1999.
PUBDATE: 20031001
We analysed incidence data of basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) of the skin from the Cancer Registry Saarland, Germany. During 1995-1999, the age-standardised incidence rates (world standard population) of BCC and SCC were 43.7 and 11.2 per 100000 among men and 31.7 and 4.4 per 100000 among women.


7. DOCID:31548 SCORE: 0.000249629067754512
DOCNO: 12925068
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Magnetic Resonance Imaging
QUALIFIER: pathology
AUTHOR: R G H Beets-Tan RG
AFFILIATION: Department of Radiology, University Hospital Maastricht, PO Box 5800, 6202 AZ Maastricht, the Netherlands. rbe@rdia.azm.nl
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.
COUNTRY: England
TITLE: MRI in rectal cancer: the T stage and circumferential resection margin.
PUBDATE: 20030901
Different stages of rectal cancer show differing degrees of risk for local recurrence. Paramount for the selection and differentiated treatment of the different risk groups is a reliable preoperative test that can distinguish between these subgroups. There is recent evidence suggesting that MRI can serve for this purpose, because it accurately predicts the circumferential resection margin. In this article the role of MRI in the preoperative management of rectal cancer patients will be discussed.


8. DOCID:28058 SCORE: 0.000249627573324285
DOCNO: 12565007
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: therapeutic use
QUALIFIER: therapeutic use
QUALIFIER: drug therapy
QUALIFIER: trends
QUALIFIER: therapeutic use
QUALIFIER: therapeutic use
AUTHOR: Andrew D Westwell AD
AFFILIATION: School of Pharmaceutical Sciences, University of Nottingham, University Park, Nottingham, UK NG7 2RD. Andrew.Westwell@nottingham.ac.uk
PUBTYPE: Journal Article
JOURNALTITLE: Drug discovery today.
COUNTRY: England
TITLE: A new era in cancer therapeutics?
PUBDATE: 20030101
Highlights from the 14th EORTC-NCI-AACR Symposium Molecular Targets and Cancer Therapeutics, 19-22 November 2002, in Frankfurt, Germany.


9. DOCID:28555 SCORE: 0.000249627405459858
DOCNO: 16121704
OWNER: NLM
STATUS: In-Process
AUTHOR: Tomasz Switaj T
AUTHOR: Witold Lasek W
AFFILIATION: Center of Oncology--Institute Soft Tissue/Bone Sarcoma and Melanoma Department, Roentgena 5, Warsaw 02-781, Poland. tswitaj@ib.amwaw.edu.pl
PUBTYPE: Journal Article
JOURNALTITLE: Current opinion in molecular therapeutics.
COUNTRY: England
TITLE: Technology evaluation: HYB-2055, Hybridon.
PUBDATE: 20050801
Hybridon is developing immunomodulatory oligonucleotides. including injectable HYB-2055 (IMOxine) which acts as an agonist of toll-like receptor 9, for the potential treatment of cancer. HYB-2055 is currently undergoing phase II clinical trials. The immunomodulatory oligonucleotides are also being investigated for the potential treatment of infectious diseases and immune disorders.


10. DOCID:28300 SCORE: 0.000249625765942347
DOCNO: 15157868
AUTHOR: Anthony C Bishop AC
AFFILIATION: Amherst College, Department of Chemistry, Amherst, MA 01002 USA.
PUBTYPE: Comment
PUBTYPE: Journal Article
JOURNALTITLE: Chemistry & biology.
COUNTRY: England
TITLE: A hot spot for protein kinase inhibitor sensitivity.
PUBDATE: 20040501
ATP binding site-directed protein kinase inhibitors are potent weapons in the war on cancer. However, specific mutations at an inhibitor-sensitivity "hot spot" can render these molecules ineffective. In this issue of Chemistry & Biology, Daub and coworkers have used an array of known kinase inhibitors to systematically characterize the desensitizing effects of hot spot mutations.


11. DOCID:30295 SCORE: 0.000249624443432751
DOCNO: 12624825
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Phytotherapy
DESCRIPTOR: Vernonia
QUALIFIER: pharmacology
QUALIFIER: pharmacology
QUALIFIER: pharmacology
AUTHOR: J L Koul JL
AUTHOR: S Koul S
AUTHOR: C Singh C
AUTHOR: S C Taneja SC
AUTHOR: M Shanmugavel M
AUTHOR: H Kampasi H
AUTHOR: A K Saxena AK
AUTHOR: G N Qazi GN
PUBTYPE: Letter
JOURNALTITLE: Planta medica.
COUNTRY: Germany
TITLE: In vitro cytotoxic elemanolides from Vernonia lasiopus.
PUBDATE: 20030201
Two new elemanolides, epivernodalol and lasiopulide, were isolated after chromatographic separation of the alcoholic extract of the dried aerial parts of the Vernonia lasiopus. These elemanolides are new C-10 epimers of the sesquiterpene lactones vernodalol and demethylacroylated vernodalol isolated from other species of Vernonia. Both elemanolides showed in vitro cytotoxicity against human cancer cell lines in culture. This is the first report of isolation and cytotoxic activity of the two elemanolides from V. lasiopus.


12. DOCID:29137 SCORE: 0.000249624118967662
DOCNO: 14998484
AUTHOR: Joachim Kienast J
AUTHOR: Wolfgang E Berdel WE
AFFILIATION: Department of Medicine, Hematology and Oncology, University of Muenster, D-48129 Muenster, Germany. kienast@uni-muenster.de
PUBTYPE: Comment
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Cancer cell.
COUNTRY: United States
TITLE: c-maf in multiple myeloma: an oncogene enhancing tumor-stroma interactions.
PUBDATE: 20040201
Gene expression profiling studies reported by Hurt et al. in this issue of Cancer Cell reveal an unexpectedly frequent overexpression of c-maf in multiple myeloma and identify molecular targets of c-maf transactivation. The results define c-maf as a prototype of a class of oncogenes that not only stimulate cell cycle progression, but also promote pathological interactions between tumor and stroma cells.


13. DOCID:28292 SCORE: 0.000249624107235873
DOCNO: 16109367
AUTHOR: Peter K Vogt PK
AUTHOR: Andreas G Bader AG
AFFILIATION: Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, California 92037, USA.
PUBTYPE: Comment
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Molecular cell.
COUNTRY: United States
TITLE: Jun: stealth, stability, and transformation.
PUBDATE: 20050801
A recent paper by Wei and collaborators in Cancer Cell sheds light on the effects of one of the mutations in v-Jun and has broad implications for our understanding of control mechanisms that direct the timing of important cell cycle functions (Wei et al., 2005).


14. DOCID:28000 SCORE: 0.000249623208693162
DOCNO: 11179497
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: therapeutic use
QUALIFIER: drug therapy
QUALIFIER: analogs & derivatives
AUTHOR: A J Weiss AJ
AUTHOR: R D Lackman RD
AFFILIATION: Department of Medicine, Allegheny General University School of Medicine, Philadelphia, PA 19107, USA.
PUBTYPE: Journal Article
JOURNALTITLE: International journal of oncology.
COUNTRY: Greece
TITLE: Concurrent administration of vinorelbine with human recombinant granulocyte-macrocyte stimulating factor.
PUBDATE: 20010301
Thirty-three patients with incurable neoplasms resistant to standard therapy received vinorelbine 10 mg/m(2)/day by continuous infusion with concurrent administration of rHGM-CSF 4 microg/m(2)/day. The duration of the vinorelbine infusion was individualized; the infusion was continued until early evidence of hematopoietic toxicity was noted. The concurrent administration of GM-CSF permitted a substantial increase in dose intensity of the anti-cancer agent without a corresponding increase in drug toxicity. There was no evidence that the anti-tumor effect of vinorelbine was compromised by the concurrent administration of GM-CSF.